Raffaele Colucci
Scorrano, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
Journal: American journal of therapeutics
Published: July 23, 2026
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
Journal: American journal of therapeutics
Published: July 23, 2026
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.
Journal: Advances in therapy
Published: February 11, 2026
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.
Journal: Journal of clinical medicine
Published: August 27, 2025
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.
Journal: Journal of clinical medicine
Published: September 23, 2024
Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international study.
Journal: Intestinal research
Published: March 22, 2024
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Journal: Expert opinion on biological therapy
Published: January 22, 2024
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Journal: Expert opinion on pharmacotherapy
Published: June 26, 2023
Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason.
Journal: Frontiers in gastroenterology (Lausanne, Switzerland)
Published: May 06, 2023
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis.
Journal: The American journal of gastroenterology
Published: March 08, 2023
Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndrome.
Journal: Minerva gastroenterology
Published: March 01, 2023
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Journal: Expert opinion on biological therapy
Published: February 27, 2023
Last Updated: 09/26/2026